IOVA
Iovance Biotherapeutics, Inc.
September 29, 2026 · pre-market
- Rarity
- 3.33
- Peak move
- +38.98%
- Float cap
- $3.9B
Iovance Biotherapeutics is a commercial-stage biopharmaceutical company developing and delivering tumor infiltrating lymphocyte (TIL) cell therapies for patients with solid tumor cancers. It sells Amtagvi (lifileucel), a one-time individualized T cell therapy for previously treated advanced melanoma, and Proleukin (aldesleukin), an IL-2 product used in the Amtagvi regimen and other oncology, manufacturing, and research applications. Products are provided through authorized treatment centers, distributors, and third-party clients.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
3 events · 1 from SEC or newswire · 0 timed with the moveguidance_changeIovance Biotherapeutics raised its full-year 2026 total revenue guidance to $410-$420 million from a prior $350-$370 million range, a $55 million (~15%) increase at the midpoint, citing U.S. demand for Amtagvi (lifileucel) and Proleukin.
SEC8-K 0001104659-26-111583wireglobenewswire.comWebfinancialcontent.comWebir.iovance.comWebglobenewswire.comexecutive_remarkInterim President and CEO Frederick Vogt said increasing patient demand and the current manufacturing schedule give strong visibility into third and fourth quarter 2026 revenues, with the ATC network at about 100 centers and on track for at least 110 by year-end 2026.
operating_metricsIovance said its authorized treatment center network has grown to about 100 centers and it remains on track to reach at least 110 ATCs by year-end 2026, with Q2 2026 total product revenue of $99.3 million cited as supporting the raised outlook.